Condition (MeSH)
Heart Valve Prolapse
ClinicalTrials.gov lists 48 trials for Heart Valve Prolapse or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
1 of the 48 trials are tagged with Heart Valve Prolapse itself; the rest are tagged with a narrower condition beneath it.
When did Heart Valve Prolapse trials start? (21)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Not applicable
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 4 |
| 2024 | 3 |
| 2023 | 4 |
| 2022 | 1 |
| 2021 | 3 |
| 2020 | 2 |
| 2018 | 4 |
| 2017 | 1 |
| 2016 | 4 |
Showing 10 of 21 earlier years.
No forecast is made for this condition: it averages 2.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Heart Valve Prolapse trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 1/2 | 1 |
| Phase 2 | 1 |
| Phase 3 | 1 |
| Not applicable | 18 |
| Observational | 25 |
How many Heart Valve Prolapse trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 8 |
| Active, not recruiting | 3 |
| Completed | 21 |
| Terminated | 2 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Heart Valve Prolapse trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Abbott Medical Devices | 5 |
| Edwards Lifesciences | 5 |
| NeoChord | 4 |
Which drugs are being tested for Heart Valve Prolapse? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Flecainide | 1 |
Interventions as named in the registry (3)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Metoprolol XL | 1 |
| Blood collection | 1 |
| Blood Biomarkers | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Heart Valve Prolapse trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Death | 546 | 4 |
| Congestive heart failure | 361 | 3 |
| Other | 144 | 2 |
| Atrial arrhythmia | 131 | 3 |
| Pneumonia | 127 | 4 |
Showing 5 of 10 adverse events.
Which publications cover Heart Valve Prolapse? (3)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Paravalvular regurgitation after transcatheter aortic valve replacement with the Edwards sapien valve in the PARTNER trial: characterizing patients and impact on outcomes. | European heart journal | 2015 | No |
| Diffusion-weighted MRI determined cerebral embolic infarction following transcatheter aortic valve implantation: assessment of predictive risk factors and the relationship to subsequent health status. | Heart (British Cardiac Society) | 2012 | No |
| [Treating mitral regurgitation: a surgical and interventional update]. | Herz | 2011 | No |
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.